CRN Recognizes Arcserve’s Shawn Massey as One of 2022’s 100 People You Don’t Know But Should
CRN’s annual list honors those who may not be in the spotlight but whose contributions…
Month: September 2022
Quantum Frederick Continues Momentum
Quantum Loophole Signs Multiple Data Center Operator Commitments on Maryland Campus with the QLoop Network…
Rivelin Robotics To Introduce NetShape Robots For Metal AM Post-Processing At Formnext 2022
(Sheffield, UK. 26th September, 2022.) Rivelin Robotics is pleased to announce that it will be…
Global Ed-Tech Leader Releases Moodle Workplace 4.0 And A New User Experience In Its Enterprise LMS
Perth, Australia: Today, Moodle announced the release of Moodle Workplace 4.0 and an improved user…
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosed…
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a…
Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022
ISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial…
Neuronetics Launches Innovations To NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
Upgrades will enhance and automate the patient candidate experience for all NeuroStar providers, leading to…
Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803
KELOWNA, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) — Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB:…
Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)
Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Paratek’s Management Team BOSTON,…
Biofrontera Inc.’s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards
WOBURN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company…
AmMax Bio Provides Update on AMB-05X Program for Tenosynovial Giant Cell Tumor (TGCT)
New Patents Issued and Fast Track Designation Support Development of the Only Locally-Administered Drug Treatment…
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
– Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target…
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with…
Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America
WARRINGTON, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology…
TFF Pharmaceuticals to Participate in the Roth Inaugural Healthcare Opportunities Conference
FORT WORTH, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage…
Enzo Biochem, Inc. Launches AMPIVIEW™ Gene Expression Platform with First Products Targeting Detection of HPV and SARS-CoV-2
Powered by Enzo’s LoopRNA™ ISH technology, a new platform designed for superior sensitivity in detection…
eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer
SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc….
Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis
Study met both co-primary endpoints and all secondary endpoints At week eight, 67.3% of individuals…
Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (Celularity), a…